(0.12%) 5 303.27 points
(0.34%) 40 004 points
(-0.07%) 16 686 points
(0.97%) $80.00
(5.73%) $2.64
(1.44%) $2 419.80
(6.36%) $31.78
(2.18%) $1 094.70
(-0.02%) $0.920
(-0.18%) $10.68
(-0.27%) $0.787
(0.19%) $91.05
@ $25.11
Išleistas: 14 vas. 2024 @ 22:41
Grąža: 31.80%
Ankstesnis signalas: vas. 13 - 22:43
Ankstesnis signalas:
Grąža: 3.95 %
Live Chart Being Loaded With Signals
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders...
Stats | |
---|---|
Šios dienos apimtis | 626 199 |
Vidutinė apimtis | 864 498 |
Rinkos kapitalizacija | 2.54B |
EPS | $0 ( 2024-04-25 ) |
Kita pelno data | ( $-1.230 ) 2024-08-01 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -4.30 |
ATR14 | $0.0470 (0.14%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-05-08 | Southwell David P | Sell | 1 650 | Common Stock |
2024-05-07 | Golden Lee Scott | Sell | 175 | Common Stock |
2024-04-19 | Klein Matthew B. | Sell | 3 361 | Common Stock |
2024-04-17 | Pauwels Eric | Sell | 787 | Common Stock |
2024-04-17 | Klein Matthew B. | Sell | 1 307 | Common Stock |
INSIDER POWER |
---|
73.53 |
Last 98 transactions |
Buy: 1 038 941 | Sell: 203 269 |
Tūris Koreliacija
PTC Therapeutics Inc Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
PTC Therapeutics Inc Koreliacija - Valiuta/Žaliavos
PTC Therapeutics Inc Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $937.82M |
Bruto pelnas: | $649.70M (69.28 %) |
EPS: | $-8.37 |
FY | 2023 |
Pajamos: | $937.82M |
Bruto pelnas: | $649.70M (69.28 %) |
EPS: | $-8.37 |
FY | 2022 |
Pajamos: | $698.80M |
Bruto pelnas: | $654.12M (93.61 %) |
EPS: | $-7.79 |
FY | 2021 |
Pajamos: | $538.59M |
Bruto pelnas: | $506.27M (94.00 %) |
EPS: | $-7.26 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
PTC Therapeutics Inc
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.